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Introduction 
Muscular dystrophies (MDs) are a group of severe disorders characterized by fiber 
degeneration, progressive muscle loss and premature death. No curative treatment exists 
despite the development of pharmacological, molecular-based, and cell therapy strategies. 
Intramuscular (IM) delivery of myoblasts could be an elective treatment for small to medium size 
muscles accessible for injections. Nevertheless, it seemed inappropriate to treat numerous large 
ones, considering the invasiveness of the injection protocol, which prompted the search for 
alternative cell types able to be distributed by the circulation. Some stem cells have been 
described as exhibiting myogenic fate after delivery into damaged or diseased muscle, 
opening up new therapeutic opportunities.  
 
In this context, we isolated a muscle-derived stem cell population (termed MuStem cells) from 
healthy dogs and showed that their systemic delivery into immunosuppressed dystrophic dogs 
leads to muscle regeneration and long-term clinical stabilization. Recently, we isolated the 
human counterpart (hMuStem cells) and showed a contribution to myofiber formation after 
IM injection into damaged muscle of immunodeficient mice, placing these cells as an attractive 
candidate for cell therapy of MDs. Considering the specificities of the mouse that regularly lead to 
poor clinical predictability of studies done in this species, the hMuStem cell behavior now 
needs to be investigated into a clinically more relevant context.  
 
 
Thus, the aim of the present study is to explore the regenerative potential of hMuStem 
cells after IM administration in non-human primates (NPHs), using a protocol of cell 
administration and immunosuppression similar to that already used in the clinical 
trials that gave the best results in terms of molecular correction in dystrophic patients.  
 
Materials & Methods 
 
 
Conclusion 
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Animals. The study included 3 female cynomolgus (Macaca 
fascicularis, age range 3 to 4 years). Immunosuppression was 
started 5-7 days before transplantation) with a combination of: (a) 
Advagraf (Astellas Pharma Inc.), an extended release oral 
formulation of tacrolimus for clinical use: once a day, starting with 
5 mg/kg/day and adjusting the dose to reach different tacrolimus 
blood levels (quantified by liquid chromatography tandem mass 
spectrometry in blood samples taken just before the Advagraf 
administration of the sampling day). (b) Dexamethasone: oral, 1 
mg/day. For transplantation, monkeys were kept under general 
anaesthesia. All the procedures was authorized by the Laval 
University Animal Care Committee. 
 
hMuStem cell isolation and characterization. Human muscle-
derived cells were isolated from skeletal muscles of 9 to 15-year-
old patients free of known muscle disease. Cells were isolated 
based on a modified version of preplating protocol initially 
described by Rouger et al., 2011. hMuStem cells were then 
cultivated on coated-plastic flasks in proliferation medium 
containing 10% human serum, PSF and human recombinant 
growth factors. For phenotypic characterization hMuStem cells 
were analyzed by FACS using a panel of myogenic, 
mesenchymal and pericytes markers. Myogenic differentiation 
was assessed based on cell morphology and the sarcomeric 
myosin heavy chain (sMyHC) expression. For in vivo myogenic 
potential demonstration, 3.105 hMuStem cells (n=4, batches) 
were independently injected in cryodamaged Tibialis anterior 
muscle of Rag2-IL2rβ- mice (n=3 per cell batch). Three weeks 
later, tissue localization of hMuStem cells was determined by 
using co-immunolabelling dedicated to specific human and 
murine proteins. Nuclei were stained with DAPI.  
 
 
 
In vitro qualification of human MuStem cells 
 
 
Validation of the experimental context 
-  Characterization of hMuStem cells as early myogenic progenitors 
with myogenic potential  
-  Proof of feasibility of the hMuStem cell implantation into 
immunosuppressed NHP muscle  
-    
-  Demonstration of ability to fuse with host muscle fibers and 
participate to regeneration 
MuStem cells exhibit regenerative potential 
positioning them as a promising tool for 
cell-based therapy of muscular dystrophies  
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Tissular exploration. Necropsis of hMuStem cell-injected muscle were 
taken at 4 weeks (n=2) and 9 weeks (n=1) post-transplantation and mounted 
in embedding medium, snap-frozen in liquid nitrogen, and stored at -80ºC 
until performing serial sections of 10 µm in cryostat. Tissue localisation of 
hMuStem cells was determined using enzymatique revelation of β-
galactosidase activity. Histological analysis were performed using 
hematoxylin eosin safran (HES) and Kernechtrot staining.  
CD56 CD29 
Myogenic markers 
CD73 CD90 
Mesenchymal markers 
CD140b CD146 
Pericytes markers 
ü  Early myogenic - committed progenitors with 
mesenchymal / pericyte signature. 
ü  High proliferation rates (20.3±4.2 
population doubling level in 38 days, 
n=6). 
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ü  In vitro contribution to myotube 
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hMuStem cells: a promising source of adult muscle-derived stem cells for muscle disease therapy  
hMuStem cell transplantation. In vitro expanded hMuStem cells were 
labeled with a nuclear lacZ expression using recombinant nuclear-localizing 
site (nls-lacZ) retroviral particles. Three batches of nls-lacZ-transduced cells 
were independently injected into the left Quadriceps femoris of three 
monkeys (n=9 injected site). Transplantation was performed percutaneously 
using matrices of 100 parallel equidistant injections of 5 µL in about 1 cm3 of 
muscle with 250-µl Hamilton syringe attached to a PB600-1 repetitive device 
(Hamilton, Reno, NV, USA). A range of 4.105  to 4.106 cells were delivered 
per site. To identify the injected muscle sites for later necropsis, stitches of 
suture were placed on both sides of each transplantation site. 
Histological validation of graft take 
 
ü  Maintenance of stable 
body weight.  
Clinical settings 
Validation of an immunosuppressive protocol to obtain 
tacrolemia compatible to those obtained in clinic 
Engraftment capacities of hMuStem cells in NHP muscle tissue  
ü  No immune infiltration colocalized with 
transplanted cells after 4 and 9 weeks. 
ü  Detection of graft-derived myonuclei (blue 
nuclei) on every injected muscle sites 
(n=9). 
ü  hMuStem cell nuclei almost exclusively within NHP fibers 
in peripheric (blue arrows) and central (white arrows) 
position at 4 and 9 weeks (B, D and E). 
 Fusion capacity and regeneration participation 
ü  Chimeric myotubes (E) composed of human (white) and 
NHP (orange) nuclei in central position. 
 
 Capacity to interact with host fibers for 
 regenerative  process 
ü  Numerous hMuStem cell implantation foci in NHP muscle 
tissu at 4 and 9 weeks (A and C). Each foci are composed 
of several positive muscle fibers (inset, x400). 
 Implantation demonstration 
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ü  Maintenance of stable Tacrolimus blood 
level under 40 µg/L. 
No sign of immune graft rejection 
Successful graft acceptance of hMuStem cells at 4 and 9 weeks after administration 
A B 
Representative pictures of n=9 hMuStem cells-injected sites at 4 weeks (A, x10) and 9 weeks 
(B, x20) post-transplantation. Histoenzymatic revelation of β-galactosidase activity. 
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Lorant et al., 2018 
Representative pictures of n=6 hMuStem cells-injected site at 4 weeks post-administration. 
Histoenzymatic revelation of β-galactosidase activity with Kernechtrot (A, x40) and HES (B, x400) 
staining. 
Representative pictures of n=3 hMuStem cells-injected site at 9 weeks post-administration. 
Histoenzymatic revelation of β-galactosidase activity with Kernechtrot (C, x40) and HES 
staining on transverse (D, x400) and longitudinal (E, x400) muscle section. 
+ 4 weeks post-transplantation + 9 weeks post-transplantation 
Demonstration of hMuStem cell contribution to muscle fiber regeneration 
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Experimental design. 
